What The Biggest Investors Are Doing About Opko Health Stock's Dismal Performance

So far in 2017, Opko Health (NASDAQ:OPK) has lost roughly one-third of its market cap. The stock finished 2016 down 7% due to an end-of-year plunge.

Things aren't going well for multiple reasons. That big drop at the end of last year stemmed from disappointing results from a late-stage study of Opko's experimental long-acting human growth hormone product (hGH-CTP) in adults.

Back to news